Knobbe/Martens: Intellectual Property Law

Hatch-Waxman Litigation

For decades, Knobbe Martens has ably guided the world’s largest and most successful generic pharmaceutical companies in bringing their versions of best-selling and well-known drugs to market. Our experience and understanding of the critical business issues facing pharmaceutical companies today shape the legal solutions and winning strategies we consistently provide.

Our advice spans every aspect of pharmaceutical-related intellectual property. Our team remains focused on maximizing opportunities for clients seeking to monetize their research and development, safeguard their IP rights, and properly execute their regulatory filings in order to mitigate potential problems or roadblocks down the road.

In addition to high-stakes litigation under the Hatch-Waxman Act, we pursue and defend inter partes reviews and other post-grant proceedings. Moreover, we provide clients with strategic counseling and advice regarding settlement and other negotiations, as well as prepare pre-suit analysis, Paragraph IV and opinion letters, and settlement and license agreements.

Attorney Finder